Home Cart Sign in  
Chemical Structure| 215543-92-3 Chemical Structure| 215543-92-3

Structure of SU 5402
CAS No.: 215543-92-3

Chemical Structure| 215543-92-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SU 5402 is an effective multi-target receptor tyrosine kinase inhibitor, targeting VEGFR2, FGFR1, and PDGFRβ, with IC50 values of 20 nM, 30 nM, and 510 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SU 5402

CAS No. :215543-92-3
Formula : C17H16N2O3
M.W : 296.32
SMILES Code : O=C(O)CCC1=C(/C=C2C(NC3=C\2C=CC=C3)=O)NC=C1C
MDL No. :MFCD08235144

Safety of SU 5402

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of SU 5402

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • VEGFR2

    VEGFR2, IC50:20 nM

  • FGFR1

    FGFR1, IC50:30 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
human periodontal ligament cells 10 µM 24-48 hours To evaluate the effect of SU5402 on reversing FGF-2-mediated inhibition of SDF-1 α expression, results showed that SU5402 could inhibit the FGF-2-reduced expression of SDF-1 α PMC3577140
primary dental pulp cells 5, 10, 20 µM 3 to 7 days Inhibited FGFR signaling pathway, reducing FGF2-mediated increases in Dmp1 and Dspp expression PMC4622321
primate astrocytes 25 µM 48 hours To assess the effect of SU5402 on primate astrocyte migration and proliferation, results showed that SU5402 completely inhibited astrocyte migration and proliferation. PMC6703582
mouse spermatogonial stem cells (mSPG) 10 µM 5 days Blocking sFGF2 signaling significantly reduced the in vitro propagation of high-density cultured mSPG, leading to decreased mitosis and increased apoptosis PMC3317562
bladder tumour cell lines 0–50 µM 5 days To evaluate the effect of SU5402 on the proliferation and viability of bladder tumour cells, results showed that SU5402 inhibited the proliferation and viability of FGFR3 mutant and wild-type cell lines at micromolar concentrations. PMC3039817
human pluripotent stem cells (hPSCs) 10 μM 8 days SU5402, in combination with CHIR99021 and DAPT, accelerates the differentiation of hPSCs into neurons and induces TUBB3 expression by day 10. PMC3516136
human pluripotent stem cells 10 µM 8 days SU5402, in combination with Activin A, further decreased the expression of the early eye field/neural retina marker Rax, indicating its role in directing cells toward the retinal pigment epithelium (RPE) fate during the optic vesicle to optic cup stages of eye development. PMC3667566
mouse embryonic fibroblasts (MEFs) 10 µM mSPG did not expand in the 5F-MCM-SU5402 medium, indicating that the IVP-promoting effect of sFGF2 was mediated by receptors both on mSPG and on MEFs under normal culture conditions PMC3317562
BHK cells 10 μM 48 hours Validation of /H9004F508-CFTR cell surface expression by flow cytometry PMC3434788
MDCK cells 10 μM 48 hours Assessment of /H9004F508-CFTR chloride channel activity by short-circuit current analysis in Ussing chambers PMC3434788

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Chronic Unpredictable Stress Model Intracerebroventricular injection 2.5 μg/day Once daily for 9 days SU5402 blocked the antidepressant behavioral effects of fluoxetine in the CUS model and blocked fluoxetine-induced cell proliferation in the PFC PMC3401338
Mice Sumf1/ mice Intraperitoneal injection 500 µM Single injection, analyzed at P21–P27 By inhibiting FGF1 signaling in vivo with SU5402, the terminal differentiation of Sumf1/ mice was unlocked. The results showed that SU5402 significantly increased the frequency of intermediate precursors and terminally differentiated CD71Ter119+ cells in the BM, indicating the rescue of the block of erythroid lineage differentiation PMC2916128
Chicken NMDA-induced retinal damage model Intravitreal injection 0.8 μg/dose Injected 6 hours and 24 hours after NMDA treatment, lasting for 3 days Inhibit FGF receptor, reduce proliferation of Müller glia PMC2774719
zebrafish spinal cord injury model injection at the lesion site 5 µg/µl single injection, observed up to 3 weeks To assess the effect of SU5402 on glial cell proliferation, migration, and axonal regeneration post-spinal cord injury in zebrafish, results showed that SU5402 inhibited glial cell proliferation and migration and prevented axonal regeneration. PMC6703582

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.37mL

0.67mL

0.34mL

16.87mL

3.37mL

1.69mL

33.75mL

6.75mL

3.37mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories